跳到正文
原文
MedPage Today·· 9 天前精选AI 评分85

FDA 批准 asundexian 用于二级预防中风

Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention

AI 导读

FDA 批准 asundexian 作为首个 FXIa 抑制剂用于二级预防中风,OCEANIC-Stroke 试验显示其能显著降低中风风险且出血风险可控。

推荐理由

FDA 批准了 asundexian 用于二级预防中风,提供了一种新的治疗选择。

正文 · 原文

— First-in-class factor XIa inhibitor was supported by the OCEANIC-Stroke trial

by Nicole Lou, Senior Staff Writer, MedPage Today

November 10, 2026 • 2 min read

The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday.

Asundexian, an oral, direct, small-molecule inhibitor of FXIa, is indicated for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Its selective mechanism of action is associated with a lower risk of complications compared with available anticoagulants.

"Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke," said Hylton Joffe, MD, MMSc, director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA's Center for Drug Evaluation and Research, in the FDA's press release. "Today's approval represents a meaningful advance for patients and healthcare providers seeking a new option for secondary stroke prevention."

The approval was backed by the large phase III OCEANIC-Stroke trial in which treatment with asundexian led to a 26% relative reduction in the incidence of ischemic stroke through 780 days compared with placebo (6.2% vs 8.4%, HR 0.74, 95% CI 0.65-0.84).

Importantly, there was no significant increase in major bleeding risk among asundexian recipients who were on a 50-mg once-daily dose (1.9% vs 1.7% with placebo, HR 1.10, 95% CI 0.85-1.44).

Of note, asundexian is not approved for stroke prevention in people with atrial fibrillation (Afib). The FXIa inhibitor failed among Afib patients in the phase III OCEANIC-AF trial, which was stopped early for lack of efficacy.

Asundexian is not to be used concomitantly with combined P-glycoprotein and strong CYP3A4 inducers (e.g., carbamazepine, rifampin, St. John's Wort), as they may decrease its effectiveness.

Asundexian is not recommended in patients with moderate or severe hepatic impairment. It should also be withheld for at least 24 hours before an invasive procedure and for at least 24 hours after thrombolysis for acute ischemic stroke, the FDA noted.

Another FXIa inhibitor, milvexian, remains under investigation for secondary stroke prevention.

来源:MedPage Today · medpagetoday.com